Stockscreener 앱 받기
45.41
6.08%
-2.94
전일 마감가:
$48.35
열려 있는:
$48.09
하루 거래량:
1.07M
Relative Volume:
0.76
시가총액:
$4.89B
수익:
-
순이익/손실:
$-176.01M
주가수익비율:
-27.34
EPS:
-1.661
순현금흐름:
$-148.97M
1주 성능:
+14.79%
1개월 성능:
+37.94%
6개월 성능:
+82.37%
1년 성능:
+227.40%
1일 변동 폭
$43.81
$48.13
1주일 범위
$39.27
$48.40
52주 변동 폭
$12.30
$48.40
엣지와이즈 Stock (EWTX) Company Profile
명칭
Edgewise Therapeutics Inc
전화
720-262-7002
주소
1715 38TH ST, BOULDER
Compare EWTX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
45.41 | 4.89B | 0 | -176.01M | -148.97M | -1.661 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
엣지와이즈 Stock (EWTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-25 | 개시 | Goldman | Neutral |
| 2025-07-30 | 개시 | Raymond James | Strong Buy |
| 2025-06-30 | 개시 | H.C. Wainwright | Buy |
| 2025-04-30 | 개시 | Guggenheim | Buy |
| 2025-04-02 | 다운그레이드 | Scotiabank | Sector Outperform → Sector Perform |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2025-01-22 | 개시 | Stifel | Hold |
| 2024-11-22 | 개시 | Evercore ISI | Outperform |
| 2024-03-07 | 개시 | Piper Sandler | Overweight |
| 2023-05-01 | 개시 | Truist | Buy |
| 2022-08-25 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-04-13 | 개시 | RBC Capital Mkts | Outperform |
| 2022-01-28 | 개시 | Goldman | Neutral |
모두보기
엣지와이즈 주식(EWTX)의 최신 뉴스
Is Edgewise Therapeutics (EWTX) on the Cusp of a Breakthrough Year - Kavout | AI
Edgewise Therapeutics Stock Rides A 5-Day Winning Streak To A 23% Gain - Trefis
Oppenheimer Initiates Edgewise Therapeutics(EWTX.US) With Buy Rating, Announces Target Price $51 - Moomoo
CYTK Stock Jumped To Over 2-Year Highs On HCM Trial Outcome – So, Why Are Analysts Bullish On Edgewise Therapeutics? - Stocktwits
Oppenheimer Initiates Edgewise Therapeutics at Outperform - Moomoo
EWTX Initiated Coverage by Oppenheimer -- Rating Set to Outperfo - GuruFocus
Edgewise Therapeutics' EDG-7500 Seen Entering 'Catalyst-Dense' Regulatory Period, Oppenheimer Says - Moomoo
Oppenheimer initiates Edgewise Therapeutics stock with outperform rating - Investing.com
Price to book forward of Edgewise Therapeutics, Inc. – NASDAQ:EWTX - TradingView
Edgewise Therapeutics stock hits all-time high at 43.96 USD - Investing.com UK
Edgewise Therapeutics stock hits all-time high at 43.96 USD By Investing.com - Investing.com South Africa
Price to earnings forward of Edgewise Therapeutics, Inc. – NASDAQ:EWTX - TradingView
Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline - AOL.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
(EWTX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Guggenheim Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Raises Target Price to $51 - Moomoo
Guggenheim raises Edgewise Therapeutics stock price target on Servier deal By Investing.com - Investing.com Canada
EWTXEdgewise Therapeutics Inc Options - Finviz
Edgewise Therapeutics(EWTX.US) Officer Sells US$7.88 Million in Common Stock - Moomoo
Edgewise Therapeutics chief scientific officer Alan Russell sells $7.88m By Investing.com - Investing.com South Africa
Edgewise Therapeutics chief scientific officer Alan Russell sells $7.88m - Investing.com
Form 4 Edgewise Therapeutics Inc For: 2 July By Investing.com - Investing.com Canada
Edgewise Therapeutics (EWTX) CSO exercises 200K options and sells 200K shares - Stock Titan
Form 4 Edgewise Therapeutics Inc For: 1 July By Investing.com - Investing.com India
Director Jonathan Fox of Edgewise Therapeutics (EWTX) receives 319-share stock grant - Stock Titan
[144] Edgewise Therapeutics, Inc. SEC Filing - Stock Titan
Form 144 | Edgewise Therapeutics(EWTX.US) Director Proposes to Sell 8.13 Million in Common Stocks - Moomoo
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - PR Newswire
Edgewise lures 2 new employees with 16,500 stock options - Stock Titan
Is Edgewise Therapeutics, Inc. (EWTX) A Good Stock To Buy Now? - Insider Monkey
EWTX Stock Hits Record High – Why Servier Is Shelling Out $2.65B For Edgewise’s Muscular Dystrophy Business - Stocktwits
EWTX News | EDGEWISE THERAPEUTICS INC (NASDAQ:EWTX) - ChartMill
Edgewise Therapeutics, Inc. Actuals & Estimates (NASDAQ:EWTX) - TradingView
(EWTX) Risk Channels and Responsive Allocation - Stock Traders Daily
EWTX Forecast — Price Target — Prediction for 2027 - TradingView
Edgewise Therapeutics, Inc. (EWTX) Price Target Raised to $59 on Positive HCM Trial Data - Yahoo Finance
Edgewise Therapeutics stock surges 8.94% to $42.30 as company gears up for EAN poster reveal - Traders Union
Why Edgewise Therapeutics (EWTX) Is Up 13.3% After Phase 2 EDG-7500 HCM Data Release - Sahm
5 Best Healthcare Stocks to Buy According to Wall Street Analysts - Insider Monkey
Edgewise Therapeutics stock hits all-time high at 40.87 USD - Investing.com
Edgewise Therapeutics stock hits all-time high at 40.87 USD By Investing.com - Investing.com Australia
Edgewise Therapeutics stock jumps 5.89 percent as company readies for BIO 2026 event - Traders Union
RBC Raises Price Target on Edgewise Therapeutics to $59 From $48, Keeps Outperform, Speculative Risk - Moomoo
Here's Why We're Not Too Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Situation - Moomoo
Edgewise Therapeutics Inc (EWTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Edgewise Therapeutics Inc (EWTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Edgewise Therapeutics Inc (EWTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Edgewise Therapeutics Inc (EWTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Edgewise Therapeutics Inc (EWTX) Institutional Confidence - TradingKey
Edgewise Therapeutics Inc (EWTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
엣지와이즈 (EWTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):